110 related articles for article (PubMed ID: 1862845)
1. [The use of a gonadotropin-releasing hormone agonist for treating gynecological diseases].
Merser LJ; Jilbert HM; Chen P
Akush Ginekol (Mosk); 1991 Feb; (2):16-20. PubMed ID: 1862845
[No Abstract] [Full Text] [Related]
2. Introduction of LHRH-antagonists into the treatment of gynaecological disorders.
Reissmann T; Diedrich K; Comaru-Schally AM; Schally AV
Hum Reprod; 1994 May; 9(5):769. PubMed ID: 7929720
[No Abstract] [Full Text] [Related]
3. [Gonadotropin-releasing hormone analogs].
Krysiak R; Okopień B; Herman ZS
Pol Merkur Lekarski; 2005 May; 18(107):585-9. PubMed ID: 16161962
[TBL] [Abstract][Full Text] [Related]
4. Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues.
van der Spuy ZM; Wood M; Fieggen G; Hendricks MS
S Afr Med J; 1993 Jul; 83(7):510-3. PubMed ID: 8211493
[TBL] [Abstract][Full Text] [Related]
5. Monthly implant of luteinizing hormone-releasing hormone agonist: a practical therapeutic approach for sex-steroid dependent gynecologic diseases.
Lemay A
Fertil Steril; 1987 Jul; 48(1):10-2. PubMed ID: 2954859
[No Abstract] [Full Text] [Related]
6. The use of gonadotrophin-releasing hormone analogues in gynaecology.
Lo KW; Lau TK
Chin Med J (Engl); 1997 Oct; 110(10):746-9. PubMed ID: 9642302
[No Abstract] [Full Text] [Related]
7. [Gynecological indications of a new progestational agent with prolonged action].
Goisis M; Candotti G
Minerva Ginecol; 1970 Mar; 22(6):339-67. PubMed ID: 5515153
[No Abstract] [Full Text] [Related]
8. The value of gonadotropin-releasing hormone-agonists together with other drugs for medical treatment and prevention.
Schindler AE
Gynecol Endocrinol; 2009 Dec; 25(12):765-7. PubMed ID: 19905992
[No Abstract] [Full Text] [Related]
9. Gonadotropin-releasing hormone agonists and estrogen-progestogen replacement therapy.
Barbieri RL
Am J Obstet Gynecol; 1990 Feb; 162(2):593-5. PubMed ID: 2137979
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacology and possibilities for use of gonadotropin releasing hormone analogs].
Breckwoldt M; Zahradnik HP; Karck U
Gynakologe; 1992 Aug; 25(4):241-6. PubMed ID: 1398253
[No Abstract] [Full Text] [Related]
11. [GnRH antagonist].
Yano T; Taketani Y
Nihon Rinsho; 2001 Jan; 59 Suppl 1():133-8. PubMed ID: 11235152
[No Abstract] [Full Text] [Related]
12. [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone].
Zeng C; Gu M; Huang H
Zhonghua Fu Chan Ke Za Zhi; 1998 Aug; 33(8):490-2. PubMed ID: 10806751
[TBL] [Abstract][Full Text] [Related]
13. Clinical applications of gonadotropin-releasing hormones in reproductive disorders.
Moghissi KS
Endocrinol Metab Clin North Am; 1992 Mar; 21(1):125-40. PubMed ID: 1576979
[TBL] [Abstract][Full Text] [Related]
14. [Estrogen-progesterone "add-back" for long-term GNRH analogue therapy].
Levy T; Ben-Rafael Z
Harefuah; 1995 Jun; 128(12):789-92. PubMed ID: 7557691
[No Abstract] [Full Text] [Related]
15. Clinical applications of GnRH agonists in gynaecology.
Preutthipan S
J Med Assoc Thai; 1993 Jan; 76 Suppl 1():11-8. PubMed ID: 8113648
[TBL] [Abstract][Full Text] [Related]
16. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy.
Khan KN; Kitajima M; Hiraki K; Fujishita A; Sekine I; Ishimaru T; Masuzaki H
Hum Reprod; 2010 Mar; 25(3):642-53. PubMed ID: 20008888
[TBL] [Abstract][Full Text] [Related]
17. Elevated level of plasma vascular endothelial growth factor after gonadotropin-releasing hormone agonist treatment for leiomyomata.
Takeda T; Osuga K; Miyake A; Wakabayashi A; Morishige K; Kimura T
Gynecol Endocrinol; 2008 Dec; 24(12):724-6. PubMed ID: 19172544
[TBL] [Abstract][Full Text] [Related]
18. GnRH-antagonists in reproductive medicine.
Griesinger G; Felberbaum R; Diedrich K
Arch Gynecol Obstet; 2005 Dec; 273(2):71-8. PubMed ID: 15991015
[TBL] [Abstract][Full Text] [Related]
19. Prediction of the effects of gonadotropin-releasing hormone agonist therapy in uterine leiomyoma by T1 contrast-enhanced magnetic resonance imaging sequences.
Kadowaki M; Murakami T; Morita J; Terada Y; Yaegashi N; Okamura K
Fertil Steril; 2002 May; 77(5):1081-2. PubMed ID: 12009376
[No Abstract] [Full Text] [Related]
20. Monitoring therapy with a gonadotropin-releasing hormone analog: utility of MR imaging.
Zawin M; McCarthy S; Scoutt L; Lange R; Lavy G; Vulte J; Comite F
Radiology; 1990 May; 175(2):503-6. PubMed ID: 2109336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
